Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:GH 30 October 2025 - 21 January 2026

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·····
Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health shares jumped 7.2% to $109.24 Tuesday, nearing their 52-week high, despite Evercore ISI downgrading the stock while raising its price target to $105. A Form 4 filing showed Chief People Officer Terilyn J. Monroe received 17,555 shares through vested stock units. Shares have climbed about 200% in the past year. Investors are watching Medicare reimbursement rates for Guardant’s Shield blood test.
6 January 2026
·
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health shares soared nearly 30% to around $94 on Oct. 30, 2025, after Q3 revenue jumped 39% to $265.2 million, beating estimates. The company raised its 2025 revenue outlook to $965–970 million. New partnerships are expanding access to its Shield colorectal cancer test nationwide. Guardant360 received additional FDA approvals and a formal review submission.
30 October 2025
··
Go toTop